Summary
Bryan Johnson, a 46-year-old tech multimillionaire focused on anti-aging, stopped using rapamycin—a supplement he took for five years—after research suggested it might accelerate aging.
Johnson cited side effects like skin infections and glucose issues, as well as findings from a recent study showing rapamycin could worsen epigenetic aging.
Known for extreme anti-aging experiments, Johnson also created the health startup Blueprint, which markets pricey supplements.
His controversial methods, including teenage blood transfusions and genital shock treatments, have raised skepticism about their effectiveness and safety.
A sample size of one is pretty much useless. The only good thing to come out of his work is the publicity and public interest in anti aging imo.
Single case design is a field of a research that can provide a great deal of value on efficacy for worth of larger trials but the way he’s approaching it, as others have said, is functionally useless. The data is likely pointless if you’ve thrown 100 confounding variables at the wall to see what sticks